Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Plasmablastic Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hodgkin Disease 1HIV Infections 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

Radiosurgery 28Magnetic Resonance Spectroscopy 15Temozolomide 14pembrolizumab 13Bevacizumab 11Nivolumab 10Ipilimumab 8Memantine 7Specimen Handling 6Radiotherapy 6Mental Status and Dementia Tests 6abemaciclib 5Blood Specimen Collection 5Radiation 4trastuzumab deruxtecan 3entrectinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Sodium Chloride 3Saline Solution 3Receptors, Interleukin-8B 3Proton Therapy 3Biopsy 3trametinib 2pertuzumab 2osimertinib 2lenvatinib 2fluciclovine F-18 2contrast agent BR1 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × carmustine, poliferprosan 20 drug combination × 90 days × Clear all
NCT04222062 2026-04-28

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

University of Nebraska

Phase 2 Recruiting
100 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡